Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific insider transaction notifications and does not contain financial performance data.
Material Changes
The filing reports an increase in the notional allocation of GSK American Depositary Shares (ADSs) on January 21, 2016. This increase resulted from the revaluation of the cash element of the notional investment held within the GSK 401(K) plan. The transaction price was $39.04 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Investor Verification Points
- Transaction Date: January 21, 2016.
- Transaction Price: $39.04 per ADS.
- Director/PDMR Activity: Dr M M Slaoui received an allocation of 25 ADSs.
- Connected Person Activity: Dr K Slaoui (Connected Person of Dr M M Slaoui) received an allocation of 9 ADSs.
- Source of Allocation: Revaluation of the cash element within the GSK 401(K) plan.